The Significance of Anti-Müllerian Hormone in the Identification of Polycystic Ovarian Syndrome among Pakistani Women

  • Aneela Mumtaz Assistant Prof Dept of Obs & Gynae. Women & children Hospital Bannu, KPK
  • Atikka Masud Department of Gynae & Obs, Foundation University and Medical College Rawalpindi
  • Najma Ayub Assistant Professor Obs & Gynae, HBS Medical & Dental College Alipur
  • Yasmeen Fatima Department of Pharmacy, Jinnah University for Women, Karachi
  • Maria Shah Pharm D, Department of Pharmacy, University of Swabi, KPK
Keywords: Polycystic Ovary Syndrome

Abstract

Objective: To assess the precision of serum Anti-Müllerian hormone (AMH) levels in identifying cases of polycystic ovary syndrome (PCOS), and to ascertain its potential as a substitute for the evaluation of polycystic ovarian morphology (PCOM) as outlined in the Rotterdam criteria.

Methodology: The research was conducted at Pak General Hospital Peshawar from January 2023 to June 2023, The ethical approval was taken from the dept. of medical research at Pak General hospital Peshawar, utilizing multiple parameters for diagnosis. Serum AMH levels were determined through the use of a commercially available Gen-II ELISA assay. Additionally, ovarian volume and the maximum follicle count in a single section were obtained through Transvaginal Sonography, executed by a single observer.

Results: The biochemical evaluation, executed at the Department of Bio-Chemistry IMS BHU, involved measuring Anti-Mullerian hormone (AMH) serum levels using an ultra-sensitive Gen-II enzyme-linked immunosorbent assay (ELISA) kit developed by Beckman Coulter, CA. The ELISA kit exhibited a lower limit of detectability (LoD) of 0.08 ng/ml, a lower limit of quantification (LoQ) of 0.17 mg/ml, and an intra-assay coefficient of variation of 5.8%. The unit of measurement was ng/mL, which equates to 7.14 pmol/L.

Conclusion: Results from the study indicated significantly elevated levels of anti-Mullerian hormone (AMH) in individuals affected by polycystic ovary syndrome (PCOS) as compared to the control group. Although AMH alone wasn't deemed a fully dependable diagnostic marker for PCOS, the findings underscored the potential benefit of integrating AMH levels as an additional parameter within the existing Rotterdam criteria. Such inclusion could potentially enhance the precision of PCOS diagnosis. Therefore, AMH levels hold promise as a valuable supplementary marker for diagnosing PCOS.

Published
2023-10-23
Section
Original Articles